1
|
Samreen A, Ali MS, Huzaifa M, Ali N, Hassan B, Ullah F, Ali S, Arifin NA. Advancements in Perovskite-Based Cathode Materials for Solid Oxide Fuel Cells: A Comprehensive Review. CHEM REC 2024; 24:e202300247. [PMID: 37933973 DOI: 10.1002/tcr.202300247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Revised: 10/15/2023] [Indexed: 11/08/2023]
Abstract
The high-temperature solid oxide fuel cells (SOFCs) are the most efficient and green conversion technology for electricity generation from hydrogen-based fuel as compared to conventional thermal power plants. Many efforts have been made to reduce the high operating temperature (>800 °C) to intermediate/low operating temperature (400 °C
Collapse
Affiliation(s)
- Ayesha Samreen
- Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
| | | | - Muhammad Huzaifa
- Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
| | - Nasir Ali
- Research Center for Sensing Materials and Devices, Zhejiang Labs, Yuhang District, Nanhu, China
| | - Bilal Hassan
- Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
| | - Fazl Ullah
- Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
| | - Shahid Ali
- Department of Physics, University of Peshawar, Peshawar, 25120, Pakistan
| | - Nor Anisa Arifin
- Materials Engineering and Testing Group, TNB Research Sdn Bhd, No.1, Kawasan Institusi Penyelidikan, Jln Ayer Hitam, 43000, Kajang, Selangor, Malaysia
| |
Collapse
|
2
|
Ahmed R, Al Shehhi A, Hassan B, Werghi N, Seghier ML. An appraisal of the performance of AI tools for chronic stroke lesion segmentation. Comput Biol Med 2023; 164:107302. [PMID: 37572443 DOI: 10.1016/j.compbiomed.2023.107302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Revised: 07/18/2023] [Accepted: 07/28/2023] [Indexed: 08/14/2023]
Abstract
Automated demarcation of stoke lesions from monospectral magnetic resonance imaging scans is extremely useful for diverse research and clinical applications, including lesion-symptom mapping to explain deficits and predict recovery. There is a significant surge of interest in the development of supervised artificial intelligence (AI) methods for that purpose, including deep learning, with a performance comparable to trained experts. Such AI-based methods, however, require copious amounts of data. Thanks to the availability of large datasets, the development of AI-based methods for lesion segmentation has immensely accelerated in the last decade. One of these datasets is the Anatomical Tracings of Lesions After Stroke (ATLAS) dataset which includes T1-weighted images from hundreds of chronic stroke survivors with their manually traced lesions. This systematic review offers an appraisal of the impact of the ATLAS dataset in promoting the development of AI-based segmentation of stroke lesions. An examination of all published studies, that used the ATLAS dataset to both train and test their methods, highlighted an overall moderate performance (median Dice index = 59.40%) and a huge variability across studies in terms of data preprocessing, data augmentation, AI architecture, and the mode of operation (two-dimensional versus three-dimensional methods). Perhaps most importantly, almost all AI tools were borrowed from existing AI architectures in computer vision, as 90% of all selected studies relied on conventional convolutional neural network-based architectures. Overall, current research has not led to the development of robust AI architectures than can handle spatially heterogenous lesion patterns. This review also highlights the difficulty of gauging the performance of AI tools in the presence of uncertainties in the definition of the ground truth.
Collapse
Affiliation(s)
- Ramsha Ahmed
- Department of Biomedical Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| | - Aamna Al Shehhi
- Department of Biomedical Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Healthcare Engineering Innovation Center (HEIC), Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| | - Bilal Hassan
- Department of Electrical Engineering and Computer Science, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| | - Naoufel Werghi
- Healthcare Engineering Innovation Center (HEIC), Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Electrical Engineering and Computer Science, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| | - Mohamed L Seghier
- Department of Biomedical Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Healthcare Engineering Innovation Center (HEIC), Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
| |
Collapse
|
3
|
Skivenes M, Falch-Eriksen A, Hassan B. Restricting family life - an examination of citizens' views on state interventions and parental freedom in eight European countries. Eur J Soc Work 2023; 27:490-504. [PMID: 38689656 PMCID: PMC11057843 DOI: 10.1080/13691457.2023.2227772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 05/02/2024]
Abstract
This paper examines the public views - a total of 10,348 persons - on restrictions of personal autonomy of others to protect the interest of children. We use representative country samples of the adult populations of Austria, England, Estonia, Finland, Germany, Ireland, Norway, and Spain, and ask them to consider an experimental vignette with three different parental conditions: substance abuse, mental health problems, and learning difficulties. The findings display that most people would restrict parental freedom to protect the child, and a stricter restriction when the parent struggles with substance abuse compared to mental health compared to learning difficulties. There are some country differences, and when examining the role of institutional context of child protective system, a correlation is detected with significant differences between population views in a right-oriented system versus a well-being system and maltreatment system. In light of the ongoing European debates about child protection and how controversial and contested this area of the welfare state seem to be, it is interesting to learn (also) from this study that people, across countries, individual differences, child protection systems, overall are supportive of state intervention and support in a situation with a child at potential risk.
Collapse
Affiliation(s)
- Marit Skivenes
- Department of Government, Centre for Research on Discretion and Paternalism, University of Bergen, Bergen, Norway
| | | | - Bilal Hassan
- Department of Government, Centre for Research on Discretion and Paternalism, University of Bergen, Bergen, Norway
| |
Collapse
|
4
|
Ellis SDP, Hamilton C, Hassan B, Pratap S, Trent S. Whole Lung Radiotherapy to Treat Metastatic Extraskeletal Myxoid Chondrosarcomas. Clin Oncol (R Coll Radiol) 2023; 35:e408-e409. [PMID: 36944557 DOI: 10.1016/j.clon.2023.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 03/06/2023] [Indexed: 03/12/2023]
Affiliation(s)
- S D P Ellis
- Department of Oncology, Churchill Hospital, Oxford, UK
| | - C Hamilton
- University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - B Hassan
- Department of Oncology, Churchill Hospital, Oxford, UK
| | - S Pratap
- Department of Oncology, Churchill Hospital, Oxford, UK
| | - S Trent
- Department of Oncology, Churchill Hospital, Oxford, UK.
| |
Collapse
|
5
|
Hassan T, Shafay M, Hassan B, Akram MU, ElBaz A, Werghi N. Knowledge distillation driven instance segmentation for grading prostate cancer. Comput Biol Med 2022; 150:106124. [PMID: 36208597 DOI: 10.1016/j.compbiomed.2022.106124] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 08/29/2022] [Accepted: 09/17/2022] [Indexed: 11/27/2022]
Abstract
Prostate cancer (PCa) is one of the deadliest cancers in men, and identifying cancerous tissue patterns at an early stage can assist clinicians in timely treating the PCa spread. Many researchers have developed deep learning systems for mass-screening PCa. These systems, however, are commonly trained with well-annotated datasets in order to produce accurate results. Obtaining such data for training is often time and resource-demanding in clinical settings and can result in compromised screening performance. To address these limitations, we present a novel knowledge distillation-based instance segmentation scheme that allows conventional semantic segmentation models to perform instance-aware segmentation to extract stroma, benign, and the cancerous prostate tissues from the whole slide images (WSI) with incremental few-shot training. The extracted tissues are then used to compute majority and minority Gleason scores, which, afterward, are used in grading the PCa as per the clinical standards. The proposed scheme has been thoroughly tested on two datasets, containing around 10,516 and 11,000 WSI scans, respectively. Across both datasets, the proposed scheme outperforms state-of-the-art methods by 2.01% and 4.45%, respectively, in terms of the mean IoU score for identifying prostate tissues, and 10.73% and 11.42% in terms of F1 score for grading PCa according to the clinical standards. Furthermore, the applicability of the proposed scheme is tested under a blind experiment with a panel of expert pathologists, where it achieved a statistically significant Pearson correlation of 0.9192 and 0.8984 with the clinicians' grading.
Collapse
Affiliation(s)
- Taimur Hassan
- KUCARS and C2PS, Department of Electrical Engineering and Computer Science, Khalifa University, Abu Dhabi, 127788, United Arab Emirates; Department of Computer and Software Engineering, National University of Sciences and Technology, Islamabad, 44000, Pakistan.
| | - Muhammad Shafay
- KUCARS and C2PS, Department of Electrical Engineering and Computer Science, Khalifa University, Abu Dhabi, 127788, United Arab Emirates
| | - Bilal Hassan
- KUCARS and C2PS, Department of Electrical Engineering and Computer Science, Khalifa University, Abu Dhabi, 127788, United Arab Emirates; School of Automation Science and Electrical Engineering, Beihang University (BUAA), Beijing, 100191, China
| | - Muhammad Usman Akram
- Department of Computer and Software Engineering, National University of Sciences and Technology, Islamabad, 44000, Pakistan
| | - Ayman ElBaz
- Department of Bioengineering, University of Louisville, Louisville, KY 40292, USA
| | - Naoufel Werghi
- KUCARS and C2PS, Department of Electrical Engineering and Computer Science, Khalifa University, Abu Dhabi, 127788, United Arab Emirates
| |
Collapse
|
6
|
Milton R, Modibbo F, Gillespie D, Alkali FI, Mukaddas AS, Kassim A, Sa'ad FH, Tukur FM, Khalid RY, Muhammad MY, Bello M, Edwin CP, Ogudo E, Iregbu KC, Jones L, Hood K, Ghazal P, Sanders J, Hassan B, Belga FJ, Walsh TR. Incidence and sociodemographic, living environment and maternal health associations with stillbirth in a tertiary healthcare setting in Kano, Northern Nigeria. BMC Pregnancy Childbirth 2022; 22:692. [PMID: 36076161 PMCID: PMC9454147 DOI: 10.1186/s12884-022-04971-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Accepted: 08/02/2022] [Indexed: 11/23/2022] Open
Abstract
Background Almost two million stillbirths occur annually, most occurring in low- and middle-income countries. Nigeria is reported to have one of the highest stillbirth rates on the African continent. The aim was to identify sociodemographic, living environment, and health status factors associated with stillbirth and determine the associations between pregnancy and birth factors and stillbirth in the Murtala Mohammed Specialist Hospital, Kano, Nigeria. Methods A three-month single-site prospective observational feasibility study. Demographic and clinical data were collected. We fitted bivariable and multivariable models for stillbirth (yes/no) and three-category livebirth/macerated stillbirth/non-macerated stillbirth outcomes to explore their association with demographic and clinical factors. Findings 1,998 neonates and 1,926 mothers were enrolled. Higher odds of stillbirth were associated with low-levels of maternal education, a further distance to travel to the hospital, living in a shack, maternal hypertension, previous stillbirth, birthing complications, increased duration of labour, antepartum haemorrhage, prolonged or obstructed labour, vaginal breech delivery, emergency caesarean-section, and signs of trauma to the neonate following birth. Interpretation This work has obtained data on some factors influencing stillbirth. This in turn will facilitate the development of improved public health interventions to reduce preventable deaths and to progress maternal health within this site. Supplementary Information The online version contains supplementary material available at 10.1186/s12884-022-04971-x.
Collapse
Affiliation(s)
- Rebecca Milton
- Centre for Trials Research, Cardiff University, Cardiff, UK.
| | - F Modibbo
- Murtala Mohammed Specialist Hospital (MMSH), Kano, Nigeria
| | - D Gillespie
- Centre for Trials Research, Cardiff University, Cardiff, UK
| | - F I Alkali
- Department of Biochemistry, Bayero University, Kano, Nigeria
| | - A S Mukaddas
- Department of Biological Sciences, Bayero University, Kano, Nigeria
| | - A Kassim
- Department of Biological Sciences, Bayero University, Kano, Nigeria
| | - F H Sa'ad
- Department of Medical Microbiology and Parasitology, Bayero University, Kano, Nigeria
| | - F M Tukur
- Department of Biological Sciences, Bayero University, Kano, Nigeria
| | - R Y Khalid
- Murtala Mohammed Specialist Hospital (MMSH), Kano, Nigeria
| | - M Y Muhammad
- Murtala Mohammed Specialist Hospital (MMSH), Kano, Nigeria
| | - M Bello
- Murtala Mohammed Specialist Hospital (MMSH), Kano, Nigeria
| | - C P Edwin
- Department of Microbiology, Aminu Kano Teaching Hospital, Kano, Nigeria
| | - E Ogudo
- Murtala Mohammed Specialist Hospital (MMSH), Kano, Nigeria
| | - K C Iregbu
- Department of Medical Microbiology, National Hospital Abuja, Abuja, Nigeria
| | - L Jones
- Department of Medical Microbiology Cardiff, Public Health Wales, University Hospital of Wales, Cardiff, UK
| | - K Hood
- Centre for Trials Research, Cardiff University, Cardiff, UK
| | - P Ghazal
- Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, UK
| | - J Sanders
- School of Healthcare Sciences, Cardiff University, Cardiff, UK
| | - B Hassan
- Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
| | - F J Belga
- Murtala Mohammed Specialist Hospital (MMSH), Kano, Nigeria
| | - T R Walsh
- Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.,Department of Zoology, Ineos Institute of Antimicrobial Research, University of Oxford, Oxford, UK
| |
Collapse
|
7
|
Fahad AK, Ruan C, Nazir R, Hassan B. Transmissive Polarizer Metasurfaces: From Microwave to Optical Regimes. Nanomaterials (Basel) 2022; 12:nano12101705. [PMID: 35630935 PMCID: PMC9144959 DOI: 10.3390/nano12101705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 05/06/2022] [Accepted: 05/12/2022] [Indexed: 11/16/2022]
Abstract
Metasurfaces, a special class of metamaterials, have recently become a rapidly growing field, particularly for thin polarization converters. They can be fabricated using a simple fabrication process due to their smaller planar profile, both in the microwave and optical regimes. In this paper, the recent progress in MSs for linear polarization (LP) to circular polarization (CP) conversion in transmission mode is reviewed. Starting from history, modeling and the theory of MSs, uncontrollable single and multiple bands and LP-to-CP conversions, are discussed and analyzed. Moreover, detailed reconfigurable MS-based LP-to-CP converters are presented. Further, key findings on the state-of-the-arts are discussed and tabulated to give readers a quick overview. Finally, a conclusion is drawn by providing opinions on future developments in this growing research field.
Collapse
Affiliation(s)
- Ayesha Kosar Fahad
- School of Electronics and Information Engineering, Beihang University, Beijing 100191, China;
| | - Cunjun Ruan
- School of Electronics and Information Engineering, Beihang University, Beijing 100191, China;
- Beijing Key Laboratory for Microwave Sensing and Security Applications, Beihang University, Beijing 100191, China
- Correspondence:
| | - Rabia Nazir
- Faculty of Electrical Engineering, University of Engineering and Technology, Lahore 100191, Pakistan;
| | - Bilal Hassan
- Department of Electrical Engineering and Computer Science, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates;
| |
Collapse
|
8
|
Hassan B, Qin S, Ahmed R, Hassan T, Taguri AH, Hashmi S, Werghi N. Deep learning based joint segmentation and characterization of multi-class retinal fluid lesions on OCT scans for clinical use in anti-VEGF therapy. Comput Biol Med 2021; 136:104727. [PMID: 34385089 DOI: 10.1016/j.compbiomed.2021.104727] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2021] [Revised: 07/31/2021] [Accepted: 08/01/2021] [Indexed: 11/19/2022]
Abstract
BACKGROUND In anti-vascular endothelial growth factor (anti-VEGF) therapy, an accurate estimation of multi-class retinal fluid (MRF) is required for the activity prescription and intravitreal dose. This study proposes an end-to-end deep learning-based retinal fluids segmentation network (RFS-Net) to segment and recognize three MRF lesion manifestations, namely, intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED), from multi-vendor optical coherence tomography (OCT) imagery. The proposed image analysis tool will optimize anti-VEGF therapy and contribute to reducing the inter- and intra-observer variability. METHOD The proposed RFS-Net architecture integrates the atrous spatial pyramid pooling (ASPP), residual, and inception modules in the encoder path to learn better features and conserve more global information for precise segmentation and characterization of MRF lesions. The RFS-Net model is trained and validated using OCT scans from multiple vendors (Topcon, Cirrus, Spectralis), collected from three publicly available datasets. The first dataset consisted of OCT volumes obtained from 112 subjects (a total of 11,334 B-scans) is used for both training and evaluation purposes. Moreover, the remaining two datasets are only used for evaluation purposes to check the trained RFS-Net's generalizability on unseen OCT scans. The two evaluation datasets contain a total of 1572 OCT B-scans from 1255 subjects. The performance of the proposed RFS-Net model is assessed through various evaluation metrics. RESULTS The proposed RFS-Net model achieved the mean F1 scores of 0.762, 0.796, and 0.805 for segmenting IRF, SRF, and PED. Moreover, with the automated segmentation of the three retinal manifestations, the RFS-Net brings a considerable gain in efficiency compared to the tedious and demanding manual segmentation procedure of the MRF. CONCLUSIONS Our proposed RFS-Net is a potential diagnostic tool for the automatic segmentation of MRF (IRF, SRF, and PED) lesions. It is expected to strengthen the inter-observer agreement, and standardization of dosimetry is envisaged as a result.
Collapse
Affiliation(s)
- Bilal Hassan
- School of Automation Science and Electrical Engineering, Beihang University (BUAA), Beijing, 100191, China.
| | - Shiyin Qin
- School of Automation Science and Electrical Engineering, Beihang University (BUAA), Beijing, 100191, China; School of Electrical Engineering and Intelligentization, Dongguan University of Technology, Dongguan, 523808, China
| | - Ramsha Ahmed
- School of Computer and Communication Engineering, University of Science and Technology Beijing (USTB), Beijing, 100083, China
| | - Taimur Hassan
- Center for Cyber-Physical Systems, Khalifa University of Science and Technology, Abu Dhabi, 127788, United Arab Emirates
| | - Abdel Hakeem Taguri
- Abu Dhabi Healthcare Company (SEHA), Abu Dhabi, 127788, United Arab Emirates
| | - Shahrukh Hashmi
- Abu Dhabi Healthcare Company (SEHA), Abu Dhabi, 127788, United Arab Emirates
| | - Naoufel Werghi
- Center for Cyber-Physical Systems, Khalifa University of Science and Technology, Abu Dhabi, 127788, United Arab Emirates
| |
Collapse
|
9
|
Detzen L, Cheat B, Besbes A, Hassan B, Marchi V, Baroukh B, Lesieur J, Sadoine J, Torrens C, Rochefort G, Bouchet J, Gosset M. NLRP3 is involved in long bone edification and the maturation of osteogenic cells. J Cell Physiol 2021; 236:4455-4469. [PMID: 33319921 DOI: 10.1002/jcp.30162] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 10/28/2020] [Accepted: 11/04/2020] [Indexed: 12/18/2022]
Abstract
Overexpression of the nucleotide-binding leucine-rich repeat protein 3 (NLRP3) inflammasome in chronic auto-immune diseases leads to skeletal anomalies, with severe osteopenia due to the activation of osteoclasts. Reproducing this phenotype in Nlrp3 knock-in mice has provided insights into the role of NLRP3 in bone metabolism. We studied the role of NLRP3 in physiological bone development using a complete Nlrp3 knock-out mouse model. We found impaired skeletal development in Nlrp3-/- mice, resulting in a shorter stature than that of Nlrp3+/+ mice. These growth defects were associated with altered femur bone growth, characterized by a deficient growth plate and an osteopenic profile of the trabeculae. No differences in osteoclast recruitment or activity were observed. Instead, Nlrp3-/- femurs showed a less mineralized matrix in the trabeculae than those of Nlrp3+/+ mice, as well as less bone sialoprotein (BSP) expressing hypertrophic chondrocytes. In vitro, primary osteoblasts lacking NLRP3 expression showed defective mineralization, together with the downregulation of BSP expression. Finally, follow-up by micro-CT highlighted the role of NLPR3 in bone growth, occurring early in living mice, as the osteopenic phenotype diminishes over time. Overall, our data suggest that NLRP3 is involved in bone edification via the regulation of hypertrophic chondrocyte maturation and osteoblast activity. Furthermore, the defect appeared to be transitory, as the skeleton recovered with aging.
Collapse
Affiliation(s)
- L Detzen
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Département de Parodontologie, Service d'Odontologie, AP-HP, Hôpital Rothschild, Paris, France
- Laboratoire d'Excellence INFLAMEX, France
| | - B Cheat
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
| | - A Besbes
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
- Faculté de Médecine Dentaire, Université de Monastir, Monastir, Tunisie
| | - B Hassan
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
| | - V Marchi
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
| | - B Baroukh
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
| | - J Lesieur
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
| | - J Sadoine
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Plateforme Imageries du Vivant, Faculté de Chirurgie Dentaire, Université de Paris, Paris, France
| | - C Torrens
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
| | - G Rochefort
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
| | - J Bouchet
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
| | - M Gosset
- UR 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, Université de Paris, Montrouge, France
- Laboratoire d'Excellence INFLAMEX, France
- Service de Médecine Bucco-Dentaire, AP-HP, Hôpital Charles Foix, Ivry/seine, France
| |
Collapse
|
10
|
Hassan B, Al-Khanati NM, Bahhah H. Effect of lingual-based flap design on postoperative pain of impacted mandibular third molar surgery: Split-mouth randomized clinical trial. Med Oral Patol Oral Cir Bucal 2020; 25:e660-e667. [PMID: 32683384 PMCID: PMC7473433 DOI: 10.4317/medoral.23666] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 06/17/2020] [Indexed: 12/02/2022] Open
Abstract
Background The extraction of third molars is one of the most common procedures in oral and maxillofacial surgery clinic. Surgical extraction involves the manipulation of both soft and hard tissues, so the patient usually experiences pain, swelling, and trismus in the immediate post-operative period. Several studies have been conducted using different types of surgical flaps to provide access with the least possible damage of soft tissues. Designing and implementing an optimum flap, which provides easier technique, better visibility, minimal post-operative complications, and best healing, is an aspired goal of every oral surgeon. This study aimed to compare lingual-based four-cornered flap with conventional triangular flap, and to evaluate its effect on post-operative pain after surgical extraction of impacted lower third molars.
Material and Methods Seventeen patients (age ranged from 19 to 26 years) with bilateral, symmetrical impacted lower third molars (n=34) were included in the study. This was a randomized clinical trial with a split-mouth design. The impacted molars were assigned randomly, by coin flipping, to two groups: Case side with lingual-based four-cornered flap (Group A), and control side with conventional triangular flap (Group B). Away from the incision, the prognosis, surgical intervention, and postoperative procedures were exactly the same for the two groups. Postsurgical pain was assessed for 5 days using visual analogue scale (VAS) and by recording patients need for analgesics on a daily basis. Patients were also evaluated via a self-reporting questionnaire, i.e. Postoperative Symptoms Severity (PoSSe) scale, administered on the seventh postoperative day.
Results Pain scores recorded in Group A were found to be significantly lower as compared to pain scores in Group B in the 5 postoperative days (P<0.05). Total analgesic intake in Group B was significantly higher (P<0.05). PoSSe scores were lower in Group A, however, this difference was insignificant (P>0.05).
Conclusions According to the data of the current study and within its limits, it appeared that lingual-based four-cornered flap design was superior to the conventional triangular flap regarding the postsurgical discomfort and pain. Key words:Impaction, third molar surgery, flap design, pain, PoSSe scale, split-mouth, RCT.
Collapse
Affiliation(s)
- B Hassan
- Department of Oral and Maxillofacial Surgery Faculty of Dentistry, Syrian Private University P.O. Box 36822, Damascus, Syria
| | | | | |
Collapse
|
11
|
Nobrega R, Bradley K, Gibbons C, Whitwell D, Hassan B, Pratap S, Sullivan M. Does avidity on FDG PET exclude the need for a percutaneous biopsy in the diagnosis of de-differentiation in retroperitoneal liposarcoma? The emerging role of the metabolic biopsy? EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32947-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
12
|
Ni M, Gu K, Hassan B, Ning D, Zheng Y, Qi Y, Xu Y. Effect of oviposition by Bactrocera dorsalis on the antioxidant activity of orange juice. BRAZ J BIOL 2019; 80:641-647. [PMID: 31644657 DOI: 10.1590/1519-6984.218661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Accepted: 03/06/2019] [Indexed: 11/22/2022] Open
Abstract
Among fruits and fruit products, oranges and orange juice are the most widely consumed worldwide. However, the effects of pest infestation of oranges on the quality of orange juice are not yet known. To evaluate the effect of the oriental fruit fly Bactrocera dorsalis on the antioxidant activity of orange juice, we measured changes in the vitamin C (Vc) concentration, total phenol content, and antioxidant activity of orange juice after the introduction of fruit fly eggs. Ten days after the eggs were introduced (larvae removed), the concentration of Vc in orange juice was 18.65 µg/mL, which was 9.16 µg/mL lower than that measured in healthy orange juice. In addition, the total phenol content decreased by 46.519 mg Gallic Acid Equivalents (GAE)/g to 9.748 mg GAE/g. Furthermore, the free-radical scavenging activity decreased from 22.297% to 5.393%. Correlation analysis indicated significant correlations between Vc concentration, total phenol content, and antioxidant activity of orange juice after B. dorsalis infestation. The decrease in Vc concentration, total phenol content and free-radical scavenging activity indicated that B. dorsalis changed the quality of orange juice by affecting the antioxidant activity of the juice after the oranges were infested.
Collapse
Affiliation(s)
- M Ni
- Department of Entomology, South China Agricultural University, Guangzhou, China
| | - K Gu
- Department of Entomology, South China Agricultural University, Guangzhou, China
| | - B Hassan
- Department of Entomology, South China Agricultural University, Guangzhou, China
| | - D Ning
- Department of Entomology, South China Agricultural University, Guangzhou, China
| | - Y Zheng
- Department of Entomology, South China Agricultural University, Guangzhou, China
| | - Y Qi
- Department of Entomology, South China Agricultural University, Guangzhou, China
| | - Y Xu
- Department of Entomology, South China Agricultural University, Guangzhou, China
| |
Collapse
|
13
|
Hassan B, Ahmed R, Li B, Noor A, Hassan ZU. A comprehensive study capturing vision loss burden in Pakistan (1990-2025): Findings from the Global Burden of Disease (GBD) 2017 study. PLoS One 2019; 14:e0216492. [PMID: 31050688 PMCID: PMC6499467 DOI: 10.1371/journal.pone.0216492] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Accepted: 04/22/2019] [Indexed: 11/23/2022] Open
Abstract
This study aims to provide estimates, trends and projections of vision loss burden in Pakistan from 1990 to 2025. Global Burden of Diseases, Injuries, and Risk Factors Study (GBD 2017) was used to observe the vision loss burden in terms of prevalence and Years Lived with Disability (YLDs). As of 2017, out of 207.7 million people in Pakistan, an estimated 1.12 million (95% Uncertainty Interval [UI] 1.07–1.19) were blind (Visual Acuity [VA] <3/60), 1.09 million [0.93–1.24] people had severe vision loss (3/60≤VA<6/60) and 6.79 million [6.00–7.74] people had moderate vision loss (6/60≤VA<6/18). Presbyopia was found to be the most common ocular condition that affected an estimated 12.64 million [11.94–13.41] people (crude prevalence 6.08% [5.75–6.45]; 61% female). In terms of age-standardized YLDs rate, Pakistan is ranked fourth among other South Asian countries and twenty-first among other 42 low-middle income countries (classified by World Bank), with 552.98 YLDs [392.98–752.95] per 100,000. Compared with 1990, all-age YLDs count of blindness and vision impairment increased by 55% in 2017, which is the tenth highest increase among major health loss causes (such as dietary iron deficiency, headache disorders, low back pain etc.) in Pakistan. Moreover, our statistics show an increase in vision loss burden by 2025 for which Pakistan needs to make more efforts to encounter the growing burden of eye diseases.
Collapse
Affiliation(s)
- Bilal Hassan
- School of Automation Science and Electrical Engineering, Beihang University, Beijing, China
- * E-mail:
| | - Ramsha Ahmed
- School of Computer and Communication Engineering, University of Science & Technology Beijing, Beijing, China
| | - Bo Li
- School of Computer Science and Engineering, Beihang University, Beijing, China
| | - Ayesha Noor
- Department of Psychology, International Islamic University, Islamabad, Pakistan
| | - Zahid ul Hassan
- Department of Pharmacology, Yusra Medical and Dental College, Islamabad, Pakistan
| |
Collapse
|
14
|
Patel DA, Xi J, Luo J, Hassan B, Thomas S, Ma CX, Campian JL. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer. Breast Cancer Res Treat 2019; 174:443-452. [PMID: 30604000 DOI: 10.1007/s10549-018-05106-7] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Accepted: 12/16/2018] [Indexed: 12/25/2022]
Abstract
PURPOSE Peripheral blood lymphopenia and elevated neutrophil-to-lymphocyte ratio (NLR) have been associated with poor outcomes in various malignancies. However, existing literature has largely focused on baseline parameters. The aim of this study is to assess the impact of radiation therapy (RT) and chemotherapy on absolute lymphocyte counts (ALC) and NLR in relation to survival outcomes in patients with triple-negative breast cancer (TNBC). METHODS A retrospective analysis was performed on 126 patients with TNBC treated at Washington University between 2005 and 2010. Cox proportional hazard model with time-varying covariates was applied to estimate the effect of time-varying ALC and NLR separately on overall survival (OS) and disease-free survival (DFS). RESULTS All patients received RT and 112 patients received either neoadjuvant chemotherapy or adjuvant chemotherapy, or both. Patients deceased had lower ALC and higher NLR compared to patients alive throughout the treatment course, even 1 year after treatment completion (ALC, 1 vs. 1.3, P = 0.03 and NLR, 3.9 vs. 2.6, P = 0.03). High ALC was associated with superior OS on both continuous and binary scales (cutoff of 1 K/ul) (HR 0.14; 95% CI 0.05-0.34; P < 0.001 and HR 0.28; 95% CI 0.13-0.61; P = 0.01, respectively). Additionally, high NLR was weakly associated with inferior OS on continuous scales (HR 1.1; 95% CI 1.06-1.15; P < 0.001). CONCLUSIONS Post-treatment lymphopenia and NLR elevation can persist until 1 year after treatment completion. Both portend shorter survival for patients with TNBC. Our data support the use of ALC and NLR to identify high risk patients who may benefit from clinical trials rather than standard of care therapy.
Collapse
Affiliation(s)
- Dilan A Patel
- Washington University School of Medicine, St. Louis, MO, 63110, USA
- Vanderbilt University School of Medicine, Nashville, TN, 37232, USA
| | - Jing Xi
- Washington University School of Medicine, St. Louis, MO, 63110, USA
- St. Luke's Hospital, St. Louis, MO, 63017, USA
| | - Jingqin Luo
- Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Bilal Hassan
- Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Shana Thomas
- Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Cynthia X Ma
- Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Jian L Campian
- Washington University School of Medicine, St. Louis, MO, 63110, USA.
- Division of Oncology, Washington University School of Medicine, Campus Box 8056, 660 South Euclid Ave, St. Louis, MO, 63110, USA.
| |
Collapse
|
15
|
Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv68-iv78. [PMID: 29846513 DOI: 10.1093/annonc/mdy095] [Citation(s) in RCA: 261] [Impact Index Per Article: 43.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Affiliation(s)
- P G Casali
- Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - N Abecassis
- Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal
| | - H T Aro
- Turku University Hospital (Turun Yliopistollinen Keskussairaala), Turlu, Finland
| | - S Bauer
- University Hospital Essen, Essen Germany
| | - R Biagini
- Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome, Italy
| | - S Bielack
- Klinikum Stuttgart-Olgahospital, Stuttgart, Germany
| | | | | | - J V M G Bovee
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - T Brodowicz
- Vienna General Hospital (AKH), Medizinische Universität Wien, Vienna, Austria
| | - J M Broto
- Hospital Universitario Virgen del Rocio-CIBERONC, Seville, Spain
| | - A Buonadonna
- Centro di Riferimento Oncologico di Aviano, Aviano
| | - E De Álava
- Hospital Universitario Virgen del Rocio-CIBERONC, Seville, Spain
| | - A P Dei Tos
- Ospedale Regionale di Treviso 'S.Maria di Cà Foncello', Treviso, Italy
| | - X G Del Muro
- Integrated Unit ICO Hospitalet, HUB, Barcelona, Spain
| | - P Dileo
- Sarcoma Unit, University College London Hospitals, London, UK
| | - M Eriksson
- Skane University Hospital-Lund, Lund, Sweden
| | - A Fedenko
- N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
| | - V Ferraresi
- Institute of Scientific Hospital Care (IRCCS), Regina Elena National Cancer Institute, Rome
| | - A Ferrari
- Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - S Ferrari
- Istituto Ortopedico Rizzoli, Bologna
| | - A M Frezza
- Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - S Gasperoni
- Azienda Ospedaliera Universitaria Careggi Firenze, Florence, Italy
| | - H Gelderblom
- Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands
| | - T Gil
- Institut Jules Bordet, Brussels, Belgium
| | - G Grignani
- Candiolo Cancer Institute, FPO IRCCS, Candiolo, Italy
| | - A Gronchi
- Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - R L Haas
- Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam and Department of Radiotherapy, Leiden University Medical Centre, Leiden, The Netherlands
| | - B Hassan
- Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | | | - R Issels
- Department of Medicine III, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany
| | - H Joensuu
- Helsinki University Central Hospital (HUCH), Helsinki, Finland
| | | | - I Judson
- The Institute of Cancer Research, London, UK
| | - P Jutte
- University Medical Center Groningen, Groningen
| | - S Kaal
- Radboud University Medical Center, Nijmegen, The Netherlands
| | - B Kasper
- Mannheim University Medical Center, Mannheim
| | | | - D A Krákorová
- Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - A Le Cesne
- Gustave Roussy Cancer Campus, Villejuif, France
| | - I Lugowska
- Maria Sklodowska Curie Institute, Oncology Centre, Warsaw, Poland
| | - O Merimsky
- Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, Israel
| | - M Montemurro
- Medical Oncology, University Hospital of Lausanne, Lausanne, Switzerland
| | - M A Pantaleo
- Azienda Ospedaliera, Universitaria, Policlinico S Orsola-Malpighi Università di Bologna, Bologna
| | - R Piana
- Azienda Ospedaliero, Universitaria Cita della Salute e della Scienza di Torino, Turin, Italy
| | - P Picci
- Istituto Ortopedico Rizzoli, Bologna
| | | | - A L Pousa
- Fundacio de Gestio Sanitaria de L'hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - P Reichardt
- Helios Klinikum Berlin Buch, Berlin, Germany
| | - M H Robinson
- YCRC Department of Clinical Oncology, Weston Park Hospital NHS Trust, Sheffield, UK
| | - P Rutkowski
- Maria Sklodowska Curie Institute, Oncology Centre, Warsaw, Poland
| | - A A Safwat
- Aarhus University Hospital, Aarhus, Finland
| | | | - S Sleijfer
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - S Stacchiotti
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
| | - K Sundby Hall
- Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
| | - M Unk
- Institute of Oncology of Ljubljana, Ljubljana, Slovenia
| | - F Van Coevorden
- Netherlands Cancer Institute Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| | | | - J Whelan
- University College Hospital, London, UK
| | - E Wardelmann
- Gerhard-Domagk-Institut für Pathologie, Universitätsklinikum Münster, Münster, Germany
| | - O Zaikova
- Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway
| | - J Y Blay
- Centre Leon Bernard and UCBL1, Lyon, France
| |
Collapse
|
16
|
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv79-iv95. [PMID: 30285218 DOI: 10.1093/annonc/mdy310] [Citation(s) in RCA: 315] [Impact Index Per Article: 52.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Affiliation(s)
- P G Casali
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan and University of Milan, Milan, Italy
| | - S Bielack
- Klinikum Stuttgart-Olgahospital, Stuttgart, Germany
| | - N Abecassis
- Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE, Lisbon, Portugal
| | - H T Aro
- Turku University Hospital (Turun Yliopistollinen Keskussairaala), Turlu, Finland
| | - S Bauer
- University Hospital Essen, Essen, Germany
| | - R Biagini
- Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome, Italy
| | | | | | - J V M G Bovee
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - B Brennan
- Royal Manchester Children's Hospital, Manchester, UK
| | - T Brodowicz
- Vienna General Hospital (AKH), Medizinische Universität Wien, Vienna, Austria
| | - J M Broto
- Hospital Universitario Virgen del Rocio-CIBERONC, Seville, Spain
| | - L Brugières
- Gustave Roussy Cancer Campus, Villejuif, France
| | - A Buonadonna
- Centro di Riferimento Oncologico di Aviano, Aviano
| | - E De Álava
- Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital /CSIC/University of Sevilla/CIBERONC, Seville, Spain
| | - A P Dei Tos
- Ospedale Regionale di Treviso "S.Maria di Cà Foncello", Treviso, Italy
| | - X G Del Muro
- Integrated Unit ICO Hospitalet, HUB, Barcelona, Spain
| | - P Dileo
- Sarcoma Unit, University College London Hospitals NHS Trust, London, UK
| | - C Dhooge
- Ghent University Hospital (Pediatric Hematology-Oncology & Stem Cell Transplantation), Ghent, Belgium
| | - M Eriksson
- Skane University Hospital-Lund, Lund, Sweden
| | - F Fagioli
- Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, University of Turin, Turin, Italy
| | - A Fedenko
- N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
| | - V Ferraresi
- Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome, Italy
| | - A Ferrari
- Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - S Ferrari
- Istituto Ortopedico Rizzoli, Bologna
| | - A M Frezza
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
| | - N Gaspar
- Gustave Roussy Cancer Campus, Villejuif, France
| | - S Gasperoni
- Azienda Ospedaliera Universitaria Careggi Firenze, Florence, Italy
| | - H Gelderblom
- Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands
| | - T Gil
- Institut Jules Bordet, Brussels, Belgium
| | - G Grignani
- Candiolo Cancer Institute, FPO IRCCS, Candiolo, Italy
| | - A Gronchi
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan and University of Milan, Milan, Italy
| | - R L Haas
- Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam and Department of Radiotherapy, Leiden University Medical Centre, Leiden, The Netherlands
| | - B Hassan
- Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | | | | | - R Issels
- Department of Medicine III, University Hospital Ludwig-Maximilians-University Munich, Munich, Germany
| | - H Joensuu
- Helsinki University Central Hospital (HUCH), Helsinki, Finland
| | | | - I Judson
- The Institute of Cancer Research, London, UK
| | - P Jutte
- University Medical Center Groningen, Groningen
| | - S Kaal
- Radboud University Medical Center, Nijmegen, The Netherlands
| | - L Kager
- St. Anna Children's Hospital & Children's Cancer Research Institute, Medical University Vienna, Vienna, Austria
| | - B Kasper
- Mannheim University Medical Center, Mannheim
| | | | - D A Krákorová
- Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - R Ladenstein
- St. Anna Children's Hospital & Children's Cancer Research Institute, Medical University Vienna, Vienna, Austria
| | - A Le Cesne
- Gustave Roussy Cancer Campus, Villejuif, France
| | - I Lugowska
- Maria Sklodowska Curie Institute-Oncology Centre, Warsaw, Poland
| | - O Merimsky
- Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, Israel
| | - M Montemurro
- Medical Oncology University Hospital of Lausanne, Lausanne, Switzerland
| | - B Morland
- Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
| | - M A Pantaleo
- Azienda Ospedaliera, Universitaria, Policlinico S Orsola-Malpighi Università di Bologna, Bologna, Italy
| | - R Piana
- Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, University of Turin, Turin, Italy
| | - P Picci
- Istituto Ortopedico Rizzoli, Bologna
| | | | - A L Pousa
- Fundacio de Gestio Sanitaria de L'Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - P Reichardt
- Helios Klinikum Berlin Buch, Berlin, Germany
| | - M H Robinson
- YCRC Department of Clinical Oncology, Weston Park Hospital NHS Trust, Sheffield, UK
| | - P Rutkowski
- Maria Sklodowska Curie Institute-Oncology Centre, Warsaw, Poland
| | - A A Safwat
- Aarhus University Hospital, Aarhus, Finland
| | - P Schöffski
- Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
| | - S Sleijfer
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - S Stacchiotti
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
| | - S J Strauss
- Sarcoma Unit, University College London Hospitals NHS Trust, London, UK
| | - K Sundby Hall
- Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
| | - M Unk
- Institute of Oncology of Ljubljana, Ljubljana, Slovenia
| | - F Van Coevorden
- Netherlands Cancer Institute Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| | - W T A van der Graaf
- Royal Marsden Hospital, London
- Radboud University Medical Center, Nijmegen, The Netherlands
- Netherlands Cancer Institute Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| | - J Whelan
- Sarcoma Unit, University College London Hospitals NHS Trust, London, UK
| | - E Wardelmann
- Gerhard-Domagk-Institut für Pathologie, Universitätsklinikum Münster, Münster, Germany
| | - O Zaikova
- Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
| | - J Y Blay
- Centre Leon Bernard and UCBL1, Lyon, France
| |
Collapse
|
17
|
Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv267. [PMID: 30188977 DOI: 10.1093/annonc/mdy320] [Citation(s) in RCA: 99] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
|
18
|
Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv268-iv269. [PMID: 30285214 DOI: 10.1093/annonc/mdy321] [Citation(s) in RCA: 138] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
|
19
|
Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv51-iv67. [PMID: 29846498 DOI: 10.1093/annonc/mdy096] [Citation(s) in RCA: 414] [Impact Index Per Article: 69.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Affiliation(s)
- P G Casali
- Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - N Abecassis
- Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal
| | - H T Aro
- Turku University Hospital (Turun Yliopistollinen Keskussairaala), Turlu, Finland
| | - S Bauer
- University Hospital Essen, Essen, Germany
| | - R Biagini
- Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome, Italy
| | - S Bielack
- Klinikum Stuttgart-Olgahospital, Stuttgart, Germany
| | | | | | - J V M G Bovee
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - T Brodowicz
- Vienna General Hospital (AKH), Medizinische Universität Wien, Vienna, Austria
| | - J M Broto
- Hospital Universitario Virgen del Rocio-CIBERONC, Seville, Spain
| | - A Buonadonna
- Centro di Riferimento Oncologico di Aviano, Aviano
| | - E De Álava
- Hospital Universitario Virgen del Rocio-CIBERONC, Seville, Spain
| | - A P Dei Tos
- Ospedale Regionale di Treviso "S.Maria di Cà Foncello", Treviso, Italy
| | - X G Del Muro
- Integrated Unit ICO Hospitalet, HUB, Barcelona, Spain
| | - P Dileo
- Sarcoma Unit, University College London Hospitals, London, UK
| | - M Eriksson
- Skane University Hospital-Lund, Lund, Sweden
| | - A Fedenko
- N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
| | - V Ferraresi
- Institute of Scientific Hospital Care (IRCCS), Regina Elena National Cancer Institute, Rome
| | - A Ferrari
- Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - S Ferrari
- Istituto Ortopedico Rizzoli, Bologna
| | - A M Frezza
- Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - S Gasperoni
- Azienda Ospedaliera Universitaria Careggi Firenze, Florence, Italy
| | - H Gelderblom
- Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands
| | - T Gil
- Institut Jules Bordet, Brussels, Belgium
| | - G Grignani
- Candiolo Cancer Institute, FPO IRCCS, Candiolo, Italy
| | - A Gronchi
- Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - R L Haas
- Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam and Department of Radiotherapy, Leiden University Medical Centre, Leiden, The Netherlands
| | - B Hassan
- Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | | | - R Issels
- Department of Medicine III, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany
| | - H Joensuu
- Helsinki University Central Hospital (HUCH), Helsinki, Finland
| | | | - I Judson
- The Institute of Cancer Research, London, UK
| | - P Jutte
- University Medical Center Groningen, Groningen
| | - S Kaal
- Radboud University Medical Center, Nijmegen, The Netherlands
| | - B Kasper
- Mannheim University Medical Center, Mannheim
| | | | - D A Krákorová
- Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - A Le Cesne
- Gustave Roussy Cancer Campus, Villejuif, France
| | - I Lugowska
- Maria Sklodowska Curie Institute, Oncology Centre, Warsaw, Poland
| | - O Merimsky
- Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, Israel
| | - M Montemurro
- Medical Oncology, University Hospital of Lausanne, Lausanne, Switzerland
| | - M A Pantaleo
- Azienda Ospedaliera, Universitaria, Policlinico S Orsola-Malpighi Università di Bologna, Bologna
| | - R Piana
- Azienda Ospedaliero, Universitaria Cita della Salute e della Scienza di Torino, Turin, Italy
| | - P Picci
- Istituto Ortopedico Rizzoli, Bologna
| | | | - A L Pousa
- Fundacio de Gestio Sanitaria de L'hospital de la SANTA CREU I Sant Pau, Barcelona, Spain
| | - P Reichardt
- Helios Klinikum Berlin Buch, Berlin, Germany
| | - M H Robinson
- YCRC Department of Clinical Oncology, Weston Park Hospital NHS Trust, Sheffield, UK
| | - P Rutkowski
- Maria Sklodowska Curie Institute, Oncology Centre, Warsaw, Poland
| | - A A Safwat
- Aarhus University Hospital, Aarhus, Finland
| | | | - S Sleijfer
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - S Stacchiotti
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
| | - K Sundby Hall
- Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
| | - M Unk
- Institute of Oncology of Ljubljana, Ljubljana, Slovenia
| | - F Van Coevorden
- Netherlands Cancer Institute Antoni van Leeuwenhoek, Amsterdam, The Netherlands
| | | | - J Whelan
- University College Hospital, London, UK
| | - E Wardelmann
- Gerhard-Domagk-Institut für Pathologie, Universitätsklinikum Münster, Münster, Germany
| | - O Zaikova
- Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway
| | - J Y Blay
- Centre Leon Bernard and UCBL1, Lyon, France
| |
Collapse
|
20
|
Hassan B, Mankowski ME, Kirker GT, Clausen CA, Ahmed S. Effects of White Mulberry (Morus alba) Heartwood Extract Against Reticulitermes flavipes (Blattodea: Rhinotermitidae). J Econ Entomol 2018; 111:1337-1345. [PMID: 29684157 DOI: 10.1093/jee/toy098] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Indexed: 06/08/2023]
Abstract
Heartwood extract from white mulberry (Morus alba L.) (Rosales: Moraceae) were investigated for antitermitic activity against Reticulitermes flavipes (Kollar) (Blattodea: Rhinotermitidae) in laboratory experiments. An ethanol:toluene (2:1) solvent system was used to remove extract from heartwood shavings. A concentration-dependent feeding response and mortality were observed for termites exposed to a concentration series range of 1.25 to 10 mg/ml of extract based on their dry weight. Results showed that maximum termite mortality occurred at 10 mg/ml. Based on the concentration series data, LC50 was calculated at 1.71 mg/ml. In filter paper feeding and repellency assays, extract significantly decreased the total number of gut protozoa compared with untreated and solvent controls. After feeding on filter paper treated at 10 mg/ml for 2 wk, protozoan populations were reduced by >55%. In choice and no-choice tests with mulberry heartwood, greater wood loss from termite feeding was found on solvent extracted blocks compared with nonextracted. Complete (100%) mortality was observed after feeding on nonextracted blocks compared with extracted blocks. Heartwood extract from white mulberry imparted resistance to vacuum pressure treated, nondurable southern pine and cottonwood. At every concentration tested, 100% mortality was observed after feeding on extract-treated southern pine or cottonwood. GC-MS analysis of extract showed high levels of the phenol compound, resorcinol. Results indicated that heartwood extract from white mulberry have antitermitic properties and might be potentially valuable in the development of environmentally benign termiticides.
Collapse
Affiliation(s)
- B Hassan
- Termite Research Laboratory, Department of Entomology, University of Agriculture Faisalabad, Faisalabad, Pakistan
| | - M E Mankowski
- USDA-FS, Wood Durability and Protection, Lincoln Green Starkville, MS
| | - G T Kirker
- USDA-FS, Wood Durability and Protection, One Gifford Pinchot Drive Madison, WI
| | - C A Clausen
- USDA-FS, Wood Durability and Protection, One Gifford Pinchot Drive Madison, WI
| | - S Ahmed
- Termite Research Laboratory, Department of Entomology, University of Agriculture Faisalabad, Faisalabad, Pakistan
| |
Collapse
|
21
|
Hassan B, Chatha SAS, Hussain AI, Zia KM, Akhtar N. Recent advances on polysaccharides, lipids and protein based edible films and coatings: A review. Int J Biol Macromol 2018; 109:1095-1107. [DOI: 10.1016/j.ijbiomac.2017.11.097] [Citation(s) in RCA: 457] [Impact Index Per Article: 76.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Revised: 11/10/2017] [Accepted: 11/15/2017] [Indexed: 12/18/2022]
|
22
|
Osmani AH, Jabbar AA, Gangwani MK, Hassan B. Outcomes of High Risk Patients with Febrile Neutropenia at a Tertiary Care Center. Asian Pac J Cancer Prev 2017; 18:2741-2745. [PMID: 29072402 PMCID: PMC5747398 DOI: 10.22034/apjcp.2017.18.10.2741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Fever during chemotherapy-induced neutropenia continues to be a major cause of morbidity and mortality in cancer patients. Mortality depends on the duration and degree of neutropenia, bacteremia, sepsis, performance status, comorbidities and other parameters. The highest mortality rates in cancer patients hospitalized with febrile neutropenia (FN) are observed in those with documented infection. The objectives of the study were to present available tools for risk assessment, to review pathogens causing infections in adult FN patients and to assess outcomes.
Collapse
Affiliation(s)
- Asif Husain Osmani
- Department of Oncology, Aga Khan University Hospital, Karachi, Pakistan.
| | | | | | | |
Collapse
|
23
|
Hassan B, Johnson KJ, Campian JL. Blood biomarker analysis to differentiate between pseudo-progression and true disease progression in post-treatment glioblastoma. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e13501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13501 Background: Current standard treatment for patients with glioblastoma (GBM) includes glucocorticoid therapy, temozolomide (TMZ), and radiation (RT) which may result in lymphotoxic and immunosuppressive effects. MRI use is currently unreliable in differentiating true from pseudo-progression pathology. Recent studies have suggested that total lymphocyte count (TLC) and CD4 cell count are associated with clinical outcomes. Our objective was to investigate whether TLC or CD4 may help to differentiate treatment effect (pesudoprogression) from tumor progression. Methods: Patients were eligible for this retrospective study if they had 1) GBM diagnosed between February 2010 and July 2015, 2) series of cell counts and clinical follow-ups monitored at Washington University, and 3) tumor progression documented by MRI and pathology. The data were analyzed using descriptive statistics, chi-square tests, Kaplan-Meier survival curves, and progression-free survival. Results: A total of 728 charts were reviewed, of which 45adults met eligibility criteria. The median age and KPS scores were 58 years and 80, respectively. MGMT was detected in 33% of patients and 69% of patients had undergone a gross total resection. Median TLC at baseline was 1700 cells/mm3 (range 400-3100). After the completion of RT/TMZ, TLC dropped 41% to a median of 1000 cells/mm3 (range 200-2900). Median TLC was 1000 cells/mm3 (range 300-2900) at the first MRI documented progression. Patients underwent surgery for this MRI documented progression. Pathology revealed that 62% of patients had true tumor progression, 33% had mixed treatment effect and residual tumor, and 4% had necrosis. The median time from diagnosis to progression was 15 months. There were no statistically significant differences in overall survival or progression free survival found in patients with higher vs lower TLC at baseline, completion of RT/TMZ, and time of progression. Conclusions: These preliminary results do not indicate that TLC level in GBM patients can differentiate between true disease progression and pseudo-progression. A larger sample size that includes patients with CD4 data is needed to confirm these results.
Collapse
Affiliation(s)
- Bilal Hassan
- Washington University in St. Louis, St. Louis, MO
| | | | - Jian Li Campian
- Washington University School of Medicine in St. Louis, St. Louis, MO
| |
Collapse
|
24
|
Patel DA, Hassan B, Luo J, Ma CX, Campian JL. The association between neutrophil to lymphocyte ratio and overall survival in patients with triple-negative breast cancer. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e12591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12591 Background: Recent reports have suggested that an elevated neutrophil to lymphocyte ratio (NLR) is associated with poor outcomes in various malignancies. Furthermore, radiation therapy (RT) alone or in combination with chemotherapy often results in reduced absolute lymphocyte counts (ALC), which has been postulated to impair host immune surveillance and anti-tumor responses. We sought to better understand whether an elevated NLR results in impaired OS in patients with triple-negative breast cancer. Methods: Our retrospective analysis was performed on a database of patients with biopsy proven triple-negative breast cancer treated at Washington University in St. Louis between 2002 and 2010. Patients who received radiation therapy and had adequate follow up in terms of clinical documentations and laboratory data were included. NLR and ALC were collected at baseline, post-adjuvant chemotherapy, prior to RT, end of RT, 2 months post RT, 1 year post RT, and completion of all planned treatments. Results: Total of 155 patients were included. We used a cutoff value of 3.0 to classify high NLR. Wilcoxon rank-sum test was used to compare NLR at each time point between deceased and alive patients. High NLR post chemotherapy is associated with worse OS (HR 1.127, 95% CI = 1.016-1.249; p<0.05). In addition, NLRs from end of RT, 2 months post and 1 year post RT are associated with worse OS: (HR 1.109, 95% CI = 1.059–1.161; p < 0.001); (HR 1.074, 95% CI = 1.041–1.109; p < 0.001); (HR 1.069, 95% CI = 1.048–1.091; p < 0.001) respectively. Conclusions: High NLR post-chemotherapy and RT are associated with worse OS in patients with triple-negative breast cancer.Further studies are warranted to establish NLR as a prognostic marker and an addition to risk prediction models. [Table: see text]
Collapse
Affiliation(s)
- Dilan Anil Patel
- Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Bilal Hassan
- Washington University in St. Louis, St. Louis, MO
| | - Jingqin Luo
- Division of Biostatistics, Washington University School of Medicine, St. Louis, MO
| | - Cynthia X. Ma
- Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Jian Li Campian
- Washington University School of Medicine in St. Louis, St. Louis, MO
| |
Collapse
|
25
|
Hassan B, Raja G, Hassan T, Usman Akram M. Structure tensor based automated detection of macular edema and central serous retinopathy using optical coherence tomography images. J Opt Soc Am A Opt Image Sci Vis 2016; 33:455-63. [PMID: 27140751 DOI: 10.1364/josaa.33.000455] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Macular edema (ME) and central serous retinopathy (CSR) are two macular diseases that affect the central vision of a person if they are left untreated. Optical coherence tomography (OCT) imaging is the latest eye examination technique that shows a cross-sectional region of the retinal layers and that can be used to detect many retinal disorders in an early stage. Many researchers have done clinical studies on ME and CSR and reported significant findings in macular OCT scans. However, this paper proposes an automated method for the classification of ME and CSR from OCT images using a support vector machine (SVM) classifier. Five distinct features (three based on the thickness profiles of the sub-retinal layers and two based on cyst fluids within the sub-retinal layers) are extracted from 30 labeled images (10 ME, 10 CSR, and 10 healthy), and SVM is trained on these. We applied our proposed algorithm on 90 time-domain OCT (TD-OCT) images (30 ME, 30 CSR, 30 healthy) of 73 patients. Our algorithm correctly classified 88 out of 90 subjects with accuracy, sensitivity, and specificity of 97.77%, 100%, and 93.33%, respectively.
Collapse
|
26
|
Hassan T, Akram MU, Hassan B, Syed AM, Bazaz SA. Automated segmentation of subretinal layers for the detection of macular edema. Appl Opt 2016; 55:454-61. [PMID: 26835917 DOI: 10.1364/ao.55.000454] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Macular edema (ME) is considered as one of the major indications of proliferative diabetic retinopathy and it is commonly caused due to diabetes. ME causes retinal swelling due to the accumulation of protein deposits within subretinal layers. Optical coherence tomography (OCT) imaging provides an early detection of ME by showing the cross-sectional view of macular pathology. Many researchers have worked on automated identification of macular edema from fundus images, but this paper proposes a fully automated method for extracting and analyzing subretinal layers from OCT images using coherent tensors. These subretinal layers are then used to predict ME from candidate images using a support vector machine (SVM) classifier. A total of 71 OCT images of 64 patients are collected locally in which 15 persons have ME and 49 persons are healthy. Our proposed system has an overall accuracy of 97.78% in correctly classifying ME patients and healthy persons. We have also tested our proposed implementation on spectral domain OCT (SD-OCT) images of the Duke dataset consisting of 109 images from 10 patients and it correctly classified all healthy and ME images in the dataset.
Collapse
|
27
|
|
28
|
Jones K, Wockner L, Brennan RM, Keane C, Chattopadhyay PK, Roederer M, Price DA, Cole DK, Hassan B, Beck K, Gottlieb D, Ritchie DS, Seymour JF, Vari F, Crooks P, Burrows SR, Gandhi MK. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma. Clin Exp Immunol 2015; 183:206-20. [PMID: 26422112 PMCID: PMC4711160 DOI: 10.1111/cei.12716] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/22/2015] [Indexed: 12/20/2022] Open
Abstract
In 40% of cases of classical Hodgkin lymphoma (cHL), Epstein–Barr virus (EBV) latency‐II antigens [EBV nuclear antigen 1 (EBNA1)/latent membrane protein (LMP)1/LMP2A] are present (EBV+cHL) in the malignant cells and antigen presentation is intact. Previous studies have shown consistently that HLA‐A*02 is protective in EBV+cHL, yet its role in disease pathogenesis is unknown. To explore the basis for this observation, gene expression was assessed in 33 cHL nodes. Interestingly, CD8 and LMP2A expression were correlated strongly and, for a given LMP2A level, CD8 was elevated markedly in HLA‐A*02–versus HLA‐A*02+ EBV+cHL patients, suggesting that LMP2A‐specific CD8+ T cell anti‐tumoral immunity may be relatively ineffective in HLA‐A*02– EBV+cHL. To ascertain the impact of HLA class I on EBV latency antigen‐specific immunodominance, we used a stepwise functional T cell approach. In newly diagnosed EBV+cHL, the magnitude of ex‐vivo LMP1/2A‐specific CD8+ T cell responses was elevated in HLA‐A*02+ patients. Furthermore, in a controlled in‐vitro assay, LMP2A‐specific CD8+ T cells from healthy HLA‐A*02 heterozygotes expanded to a greater extent with HLA‐A*02‐restricted compared to non‐HLA‐A*02‐restricted cell lines. In an extensive analysis of HLA class I‐restricted immunity, immunodominant EBNA3A/3B/3C‐specific CD8+ T cell responses were stimulated by numerous HLA class I molecules, whereas the subdominant LMP1/2A‐specific responses were confined largely to HLA‐A*02. Our results demonstrate that HLA‐A*02 mediates a modest, but none the less stronger, EBV‐specific CD8+ T cell response than non‐HLA‐A*02 alleles, an effect confined to EBV latency‐II antigens. Thus, the protective effect of HLA‐A*02 against EBV+cHL is not a surrogate association, but reflects the impact of HLA class I on EBV latency‐II antigen‐specific CD8+ T cell hierarchies.
Collapse
Affiliation(s)
- K Jones
- Blood Cancer Research, University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.,Clinical Immunohaematology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - L Wockner
- Statistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - R M Brennan
- Cellular Immunology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - C Keane
- Blood Cancer Research, University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.,Clinical Immunohaematology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.,Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
| | - P K Chattopadhyay
- ImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - M Roederer
- ImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - D A Price
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.,Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK
| | - D K Cole
- Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK
| | - B Hassan
- Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK
| | - K Beck
- Tissue Engineering and Reparative Dentistry, Cardiff University School of Dentistry, Cardiff, UK
| | - D Gottlieb
- Blood and Marrow Transplant Service, Westmead Hospital, Sydney, Australia
| | - D S Ritchie
- Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.,University of Melbourne, Melbourne, Australia
| | - J F Seymour
- University of Melbourne, Melbourne, Australia
| | - F Vari
- Blood Cancer Research, University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia
| | - P Crooks
- Blood Cancer Research, University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia
| | - S R Burrows
- Cellular Immunology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - M K Gandhi
- Blood Cancer Research, University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.,Clinical Immunohaematology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.,Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
| |
Collapse
|
29
|
Parsa A, Ibrahim N, Hassan B, Syriopoulos K, van der Stelt P. Assessment of metal artefact reduction around dental titanium implants in cone beam CT. Dentomaxillofac Radiol 2014; 43:20140019. [PMID: 25135316 DOI: 10.1259/dmfr.20140019] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVES The aim of this study was to investigate if the metal artefact reduction (MAR) tool used in the software of the ORTHOPANTOMOGRAPH(®) OP300 (Instrumentarium Dental, Tuusula, Finland) can improve the gray value levels in post-operative implant scans. METHODS 20 potential implant sites were selected from 5 edentulous human dry mandibles. Each mandible was scanned by a CBCT scanner, and images were produced under three different conditions: implant sites drilled but no implants inserted, implants inserted without application of MAR and implants inserted with application of MAR. Using Geomagic(®) Studio 2012 (Geomagic, Morrisville, NC) and 3Diagnosys(®) v. 5.3.1 (3Diemme(®) SRL, Cantù, Italy) software, three scans of each mandible were superimposed. The mean gray value of identical regions of bone around the implants was derived for each condition. The differences between gray value measurements at implant sites derived from different conditions were assessed. RESULTS A significant difference was found between mean gray values from the scans with no implants inserted and with implants inserted (with and without MAR) (p = 0.012). No significant difference was revealed for gray values measured from scans with and without MAR (p = 0.975). CONCLUSIONS The MAR tool in the software of the ORTHOPANTOMOGRAPH OP300 CBCT scanner does not significantly correct the voxel gray values affected by the metal artefact in the vicinity of an implant in human dry mandibles.
Collapse
Affiliation(s)
- A Parsa
- 1 Department of General and Specialized Dentistry, Section Oral and Maxillofacial Radiology, Academic Center for Dentistry Amsterdam (ACTA), Amsterdam, Netherlands
| | | | | | | | | |
Collapse
|
30
|
Ibrahim N, Parsa A, Hassan B, van der Stelt P, Aartman IHA, Nambiar P. Influence of object location in different FOVs on trabecular bone microstructure measurements of human mandible: a cone beam CT study. Dentomaxillofac Radiol 2013; 43:20130329. [PMID: 24265395 DOI: 10.1259/dmfr.20130329] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
The aim of this study was to assess the influence of different object locations in different fields of view (FOVs) of two cone beam CT (CBCT) systems on trabecular bone microstructure measurements of a human mandible. A block of dry human mandible was scanned at five different locations (centre, left, right, anterior and posterior) using five different FOVs of two CBCT systems (NewTom™ 5G; QR Verona, Verona, Italy and Accuitomo 170; Morita, Kyoto, Japan). Image analysis software (CTAn software v. 1.1; SkyScan, Kontich, Belgium) was used to assess the trabecular bone microstructural parameters (thickness, Tb.Th; spacing, Tb.Sp; number, Tb.N; bone volume density, BV/TV). All measurements were taken twice by one trained observer. Tb.Th, Tb.Sp and Tb.N varied significantly across different FOVs in the NewTom 5G (p < 0.001) and the Accuitomo 170 (p < 0.001). For location, a significant difference was observed only when measuring BV/TV (p = 0.03) using the NewTom 5G. The trabecular bone microstructural measurements obtained from CBCT systems are influenced by the size of FOVs. Not all trabecular bone parameters measured using different CBCT systems are affected when varying the object location within the FOVs.
Collapse
Affiliation(s)
- N Ibrahim
- Department of General and Specialized Dentistry, Section of Oral and Maxillofacial Radiology, Academic Center for Dentistry Amsterdam (ACTA), Amsterdam, Netherlands
| | | | | | | | | | | |
Collapse
|
31
|
Ibrahim N, Parsa A, Hassan B, van der Stelt P, Aartman IHA, Wismeijer D. The effect of scan parameters on cone beam CT trabecular bone microstructural measurements of the human mandible. Dentomaxillofac Radiol 2013; 42:20130206. [PMID: 24132024 DOI: 10.1259/dmfr.20130206] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The objective of this study was to investigate the effect of different cone beam CT scan parameters on trabecular bone microstructure measurements. A human mandibular cadaver was scanned using a cone beam CT (3D Accuitomo 170; J.Morita, Kyota, Japan). 20 cone beam CT images were obtained using 5 different fields of view (4×4 cm, 6×6 cm, 8×8 cm, 10×10 cm and 10×5 cm), 2 types of rotation steps (180° and 360°) and 2 scanning resolutions (standard and high). Image analysis software was used to assess the trabecular bone microstructural parameters (number, thickness and spacing). All parameters were measured twice by one trained observer. Intraclass correlation coefficients showed high intraobserver repeatability (intraclass correlation coefficient, 0.95-0.97) in all parameters across all tested scan parameters. Trabecular bone microstructural measurements varied significantly, especially in smaller fields of view (p = 0.001). There was no significant difference in the trabecular parameters when using different resolutions (number, p = 0.988; thickness, p = 0.960; spacing, p = 0.831) and rotation steps (number, p = 1.000; thickness, p = 0.954; spacing, p = 0.759). The scan field of view significantly influences the trabecular bone microstructure measurements. Rotation steps (180° or 360°) and resolution (standard or high) selections are not relevant.
Collapse
Affiliation(s)
- N Ibrahim
- Department of General and Specialized Dentistry, Section of Oral and Maxillofacial Radiology, Academic Center for Dentistry Amsterdam (ACTA), Amsterdam, Netherlands
| | | | | | | | | | | |
Collapse
|
32
|
Ibrahim N, Parsa A, Hassan B, van der Stelt P, Wismeijer D. Diagnostic imaging of trabecular bone microstructure for oral implants: a literature review. Dentomaxillofac Radiol 2013; 42:20120075. [PMID: 23420864 DOI: 10.1259/dmfr.20120075] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Several dental implant studies have reported that radiographic evaluation of bone quality can aid in reducing implant failure. Bone quality is assessed in terms of its quantity, density, trabecular characteristics and cells. Current imaging modalities vary widely in their efficiency in assessing trabecular structures, especially in a clinical setting. Most are very costly, require an extensive scanning procedure coupled with a high radiation dose and are only partially suitable for patient use. This review examines the current literature regarding diagnostic imaging assessment of trabecular microstructure prior to oral implant placement and suggests cone beam CT as a method of choice for evaluating trabecular bone microstructure.
Collapse
Affiliation(s)
- N Ibrahim
- Department of General and Specialized Dentistry, Section of Oral Radiology, Academic Center for Dentistry Amsterdam (ACTA), Gustav Mahlerlaan 3004, 1081 LA Amsterdam, Netherlands.
| | | | | | | | | |
Collapse
|
33
|
Umanjec-Korac S, Wu G, Hassan B, Liu Y, Wismeijer D. A retrospective analysis of the resorption rate of deproteinized bovine bone as maxillary sinus graft material on cone beam computed tomography. Clin Oral Implants Res 2013; 25:781-5. [DOI: 10.1111/clr.12174] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/17/2013] [Indexed: 11/27/2022]
Affiliation(s)
- S. Umanjec-Korac
- Department of Implantology and Prosthodontics; Academic Centre for Dentistry Amsterdam (ACTA); Amsterdam The Netherlands
| | - G. Wu
- Department of Implantology and Prosthodontics; Academic Centre for Dentistry Amsterdam (ACTA); Amsterdam The Netherlands
- Research Institute MOVE; VU University; Amsterdam The Netherlands
| | - B. Hassan
- Department of Implantology and Prosthodontics; Academic Centre for Dentistry Amsterdam (ACTA); Amsterdam The Netherlands
- Department of Implantology and Prosthodontics; Academic Centre for Dentistry Amsterdam (ACTA); Amsterdam The Netherlands
| | - Y. Liu
- Department of Implantology and Prosthodontics; Academic Centre for Dentistry Amsterdam (ACTA); Amsterdam The Netherlands
- Research Institute MOVE; VU University; Amsterdam The Netherlands
| | - D. Wismeijer
- Department of Implantology and Prosthodontics; Academic Centre for Dentistry Amsterdam (ACTA); Amsterdam The Netherlands
- Research Institute MOVE; VU University; Amsterdam The Netherlands
| |
Collapse
|
34
|
Hassan B, Akcakanat A, Takafumi S, Evans K, Adkins F, Meric-Bernstam F. MTOR Inhibitor MLN0128 has Antitumor Efficacy in Cell Lines With Intrinsic and Acquired Rapamycin-Resistance. J Surg Res 2013. [DOI: 10.1016/j.jss.2012.10.627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
35
|
Ibrahim N, Parsa A, Hassan B, van der Stelt P, Aartman IHA, Wismeijer D. The effect of scan parameters on cone beam CT trabecular bone microstructural measurements of human mandible. Dentomaxillofac Radiol 2013; 42:20130206. [PMID: 24404603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023] Open
Abstract
The objective of this study was to investigate the effect of different cone beam CT scan parameters on trabecular bone microstructure measurements. A human mandibular cadaver was scanned using a cone beam CT (3D Accuitomo 170; J.Morita, Kyota, Japan). 20 cone beam CT images were obtained using 5 different fields of view (4×4 cm, 6×6 cm, 8×8 cm, 10×10 cm and 10×5 cm), 2 types of rotation steps (180° and 360°) and 2 scanning resolutions (standard and high). Image analysis software was used to assess the trabecular bone microstructural parameters (number, thickness and spacing). All parameters were measured twice by one trained observer. Intraclass correlation coefficients showed high intraobserver repeatability (intraclass correlation coefficient, 0.95–0.97) in all parameters across all tested scan parameters. Trabecular bone microstructural measurements varied significantly, especially in smaller fields of view (p = 0.001). There was no significant difference in the trabecular parameters when using different resolutions (number, p = 0.988; thickness, p = 0.960; spacing, p = 0.831) and rotation steps (number, p = 1.000; thickness, p = 0.954; spacing, p = 0.759). The scan field of view significantly influences the trabecular bone microstructure measurements. Rotation steps (180° or 360°) and resolution (standard or high) selections are not relevant.
Collapse
|
36
|
|
37
|
Parsa A, Ibrahim N, Hassan B, Motroni A, van der Stelt P, Wismeijer D. Influence of cone beam CT scanning parameters on grey value measurements at an implant site. Dentomaxillofac Radiol 2012; 42:79884780. [PMID: 22933535 DOI: 10.1259/dmfr/79884780] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVES The aim of this study was to determine the grey value variation at the implant site with different scan settings, including field of view (FOV), spatial resolution, number of projections, exposure time and dose selections in two cone beam CT (CBCT) systems and to compare the results with those obtained from a multislice CT system. METHODS A partially edentulous human mandibular cadaver was scanned by three CT modalities: multislice CT (MSCT) (Philips, Best, the Netherlands), and two CBCT systems: (Accuitomo 170(®), Morita, Japan) and (NewTom 5G(®), QR, Verona, Italy). Using different scan settings 36 and 24 scans were obtained from the Accuitomo and the NewTom, respectively. The scans were converted to digital imaging and communications in medicine 3 format. The analysis of the data was performed using 3Diagnosys(®) software (v. 3.1, 3diemme, Cantù, Italy) and Geomagic studio(®) 2012 (Morrisville, NC). On the MSCT scan, one probe designating the site for pre-operative implant placement was inserted. The inserted probe on MSCT was transformed to the same region on each CBCT scan using a volume-based three-dimensional registration algorithm. The mean voxel grey value of the region around the probe was derived separately for each CBCT. The influence of scanning parameters on the measured mean voxel grey values was assessed. RESULTS Grey values in both CBCT systems significantly deviated from Hounsfield unit values measured with MSCT (p = 0.0001). In both CBCT systems, scan FOV and spatial resolution selections had a statistically significant influence on grey value measurements (p = 0.0001). The number of projections selection had a statistically significant influence in the Accuitomo system (p = 0.0001) while exposure time and dose selections had no statistically significant influence on grey value measurements in the NewTom (p = 0.43 and p = 0.37, respectively). CONCLUSIONS Grey-level values from CBCT images are influenced by device and scanning settings.
Collapse
Affiliation(s)
- A Parsa
- Department of General and Specialized Dentistry, Section Oral and Maxillofacial Radiology, Academic Center for Dentistry Amsterdam (ACTA), Gustav Mahlerlaan 3004, 1081 LA Amsterdam, the Netherlands.
| | | | | | | | | | | |
Collapse
|
38
|
Einert TR, Schmidt G, Binnig G, Balacescu O, Balacescu L, Rus M, Buiga R, Tudoran O, Todor N, Nagy V, Irimie A, Neagoe I, Yacobi R, Ustaev E, Berger RR, Barshack I, Kaur K, Henderson S, Cutts A, Domingo E, Woods J, Motley C, Dougherty B, Middleton M, Hassan B, Wang Y, Beasley E, Naley M, Schuh A, Tomlinson I, Taylor J, Planchard D, Lueza B, Rahal A, Lacroix L, Ngocamus M, Auger N, Saulnier P, Dorfmuller P, Le Chevalier T, Celebic A, Pignon JP, Soria JC, Besse B, Sun YH, Wang R, Li CG, Pan YJ, Chen HQ, Chouchane L, Shan J, Kizhakayil D, Aigha I, Dsouza S, Noureddine B, Gabbouj S, Mathew R, Hassen E, Chouchane L, Shan S, al-Rumaihi K, al-Bozom I, al-Said S, Rabah D, Farhat K, Kizhakayil D, Aigha I, Jakobsen Falk IA, Green KHZ, Lotfi K, Fyrberg A, Pejovic T, Li H, Mhawech-Fauceglia P, Hoatlin M, Guo MG, Huang M, Ge Y, Hess K, Wei C, Zhang W, Bogush TA, Dudko EA, Nureev MV, Kamensky AA, Polotsky BE, Tjulandin SA, Davydov MI, Caballero M, Hasmats J, Green H, Quanz M, Buhler C, Sun JS, Dutreix M, Cebotaru CL, Buiga R, Placintar AN, Ghilezan N, Balogh ZB, Reiniger L, Rajnai H, Csomor J, Szepesi A, Balogh A, Deak L, Gagyi E, Bodor C, Matolcsy A, Bozhenko VK, Rozhkova NI, Kudinova EA, Bliznyukov OP, Vaskevich EN, Trotsenko ID, Bozhenko VK, Rozhkova NI, Kharchenko NV, Kudinova EA, Bliznyukov OP, Kiandarian IV, Trotsenko ID, Pulito C, Terrenato I, Sacconi A, Biagioni F, Mottolese M, Blandino G, Muti P, Falvo E, Strano S, Mori F, Sacconi A, Ganci F, Covello R, Zoccali C, Biagini R, Blandino G, Strano S, Palmer GA, Wegdam W, Meijer D, Kramer G, Langridge J, Moerland PD, de Jong SM, Vissers JP, Kenter GG, Buist MR, Aerts JMFG, Milione M, de Braud F, Buzzoni R, Pusceddu S, Mazzaferro V, Damato A, Pelosi G, Garassino M, de Braud F, Broggini M, Marabese M, Veronese S, Ganzinelli M, Martelli O, Ganci F, Bossel N, Sacconi A, Fontemaggi G, Manciocco V, Sperduti I, Falvo E, Strigari L, Covello R, Muti P, Strano S, Spriano G, Domany E, Blandino G, Donzelli S, Sacconi A, Bellissimo T, Alessandrini G, Strano S, Carosi MA, Pescarmona E, Facciolo F, Telera S, Pompili A, Blandino G, de Vriendt V, de Roock W, di Narzo AF, Tian S, Biesmans B, Jacobs B, de Schutter J, Budzinska E, Sagaert X, Delorenzi M, Simon I, Tejpar S, Zhu Y, Wang HK, Ye DW, Denisov E, Tsyganov M, Tashireva L, Zavyalova M, Perelmuter V, Cherdyntseva N, Kim YC, Jang T, Oh IJ, Kim KS, Ban H, Na KJ, Ahn SJ, Kang H, Kim WJ, Park C, Abousamra NK, El-Din MS, Azmy EA. Diagnostics. Ann Oncol 2012. [DOI: 10.1093/annonc/mds161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Al-Shukaili A, Al-Kaabi J, Hassan B, Al-Araimi T, Al-Tobi M, Al-Kindi M, Al-Maniri A, Al-Gheilani A, Al-Ansari A. P2X7 receptor gene polymorphism analysis in rheumatoid arthritis. Int J Immunogenet 2011; 38:389-96. [PMID: 21645266 DOI: 10.1111/j.1744-313x.2011.01019.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The P2X7 receptor, a member of the P2X family of nucleotide-gated channels, is predominantly expressed by monocytic cells. The activation of this receptor has been associated with downstream-signalling cascades, resulting in the release of a number of inflammatory mediators. There are more than 815 single nucleotide polymorphisms (SNPs) that have been described in the human P2X7R gene, but only few have been functionally characterized. The main aim of this study is to determine whether P2X7R gene polymorphisms confer susceptibility to rheumatoid arthritis (RA). A total of 125 patients with RA and 158 healthy volunteers were enrolled in this study. DNA fragment was PCR amplified and sequenced on the AB 3130 Genetic Analyzer. No significant difference in allele frequencies of 489 C→T, 1096 C→G and 1513 A→C polymorphisms, among sporadic cases of RA and healthy controls was found. However, the 1513A/C genotype was significantly associated with the presence of rheumatoid factor and anti-MCV autoantibody in RA patients. Interestingly, the genotype frequency of 1068 A/A was 0.19 in the RA group and 0.09 in control group (P = 0.025). Consequently, this polymorphism (AA) is two folds greater in the RA group compared to controls. Moreover, this polymorphism was significantly associated with mean concentration of C-reactive protein in RA patients. In contrast, 946G→A and 1729 T→A were not detected in both groups. As a result, these two polymorphisms are uncommon in Omani Arab population. Polymorphism at position 1068 and 1513 in the P2X7R gene might contribute to the pathogenesis of RA. Moreover, the loss-of-function SNP at position 1096 C→G or the gain-of-function SNP at position 489 C→T of the P2X7 gene does not appear to be a susceptibility gene locus for the development of RA. Further studies are required to confirm this finding.
Collapse
Affiliation(s)
- A Al-Shukaili
- Department of Microbiology & Immunology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, Chaplin DJ, Rustin GJS. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011; 22:2036-2041. [PMID: 21273348 DOI: 10.1093/annonc/mdq708] [Citation(s) in RCA: 124] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer. PATIENTS AND METHODS Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks. RESULTS Five of the first 18 patients' disease responded, so the study was extended and closed after 44 patients were recruited. Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia. Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine. The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%. CONCLUSIONS The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P. A planned randomised trial will test this hypothesis.
Collapse
Affiliation(s)
- M Zweifel
- Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood
| | - G C Jayson
- School of Cancer and Enabling Sciences, University of Manchester & Christie Hospital, Manchester
| | - N S Reed
- Beatson Oncology Centre, Western Infirmary, Glasgow
| | - R Osborne
- Dorset Cancer Centre, Poole Hospital NHS Foundation Trust, Poole
| | - B Hassan
- Department of Medical Oncology, Churchill Hospital, Oxford
| | - J Ledermann
- UCL Cancer Institute, Cancer Research UK & University College of London Cancer Trials Centre, London, UK
| | - G Shreeves
- Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood
| | - L Poupard
- Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood
| | - S-P Lu
- OXiGENE Inc., San Francisco, USA
| | | | | | - G J S Rustin
- Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood.
| |
Collapse
|
41
|
Hogendoorn PCW, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PCW, Jurgens H, Paulussen M, Rozeman L, Taminiau AHM, Whelan J, Vanel D. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v204-13. [PMID: 20555083 DOI: 10.1093/annonc/mdq223] [Citation(s) in RCA: 157] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- P C W Hogendoorn
- Department of Pathology, University Medical Center, Leiden, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
A 39-year-old woman suffered from chronic a-typicalfacial pain and complaints associated with Post Traumatic Stress Disorder. The pain originated from the surgical removal of a residual tooth root under an oral implant and the stress symptoms were the consequences of the pain. Eventually, these problems had led to dismissalfrom work and family problems. She was unable to attend her dentist for a periodic oral survey due to extreme fear. Pharmacologic treatment, acupuncture, homeopathy and hypnotherapy had not improved her condition. Treatment aimed at coping with the memories of the oral treatment using 'eye movement desensitization and reprocessing' ultimately led to decline of complaints. This case report demonstrates that an oral problem may disrupt a patient's life and how psychotherapy can complete medical treatment.
Collapse
Affiliation(s)
- E Gorisse
- Uit de secties Sociale Tandheelkunde en Voorlichtingskunde en Orale Radiologie van het Academisch Centrum Tandheelkunde Amsterdam.
| | | | | |
Collapse
|
43
|
Little MA, Hassan B, Jacques S, Game D, Salisbury E, Courtney AE, Brown C, Salama AD, Harper L. Renal transplantation in systemic vasculitis: when is it safe? Nephrol Dial Transplant 2009; 24:3219-25. [DOI: 10.1093/ndt/gfp347] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Zweifel M, Jayson G, Reed N, Osborne R, Hassan B, Shreeves G, Poupard L, Walicke PA, Balkissoon J, Chaplin D, Rustin G. Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5502] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5502 Background: CA4P is a vascular disrupting agent that in pre-clinical models can increase the efficacy of a variety of therapies. A dose escalation trial of CA4P given prior to carboplatin, paclitaxel or both showed the combination was well tolerated and responses were seen in several tumor types including 6/17 with relapsed ovarian cancer. The trial was therefore extended into a phase II trial in patients with platinum resistant ovarian cancer. Methods: Patients with ovarian cancer that had relapsed and could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63mg/m2 18–20 hours prior to paclitaxel 175mg/m2 and carboplatin AUC 5 repeated 3 weekly. If > 2 responses were seen in first 18 patients 43 patients were to be treated to confirm response rate>19%. Results: Five of the first 18 patients responded so the study was extended and closed after 44 patients were recruited, with full data available to date on 34. Weekly blood counts have demonstrated grade 3/4 neutropenia in 11 and thrombocytopenia in only 1 patient. Other grade > 2 toxicity seen in > 1 patient was fatigue, nausea / vomiting, pain, alopecia, rapidly reversible ataxia, diarrhoea, neuropathy and was little different to what would be expected with paclitaxel and carboplatin. Hypertension is the commonest CA4P related toxicity and was easily controlled by GTN, then prophylactic amlodipine. Responses according to GCIG criteria, have been seen in 11/34 (32%) patients with an additional unconfirmed PR. Conclusions: The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P. A planned randomised trial will hopefully confirm this. [Table: see text]
Collapse
Affiliation(s)
- M. Zweifel
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - G. Jayson
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - N. Reed
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - R. Osborne
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - B. Hassan
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - G. Shreeves
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - L. Poupard
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - P. A. Walicke
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - J. Balkissoon
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - D. Chaplin
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| | - G. Rustin
- Mount Vernon Cancer Centre, Middlesex, United Kingdom; Christie Hospital, Manchester, United Kingdom; Beatson Cancer Centre, Glasgow, United Kingdom; Dorset Cancer Centre, Poole, United Kingdom; Churchill Hospital, Oxford, United Kingdom; Oxigene Inc, Waltham, MA
| |
Collapse
|
45
|
Steffensen S, Coelho PA, Cobbe N, Vass S, Costa M, Hassan B, Prokopenko SN, Bellen H, Heck MM, Sunkel CE. A role for Drosophila SMC4 in the resolution of sister chromatids in mitosis. Curr Biol 2001; 11:295-307. [PMID: 11267866 DOI: 10.1016/s0960-9822(01)00096-3] [Citation(s) in RCA: 146] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Faithful segregation of the genome during mitosis requires interphase chromatin to be condensed into well-defined chromosomes. Chromosome condensation involves a multiprotein complex known as condensin that associates with chromatin early in prophase. Until now, genetic analysis of SMC subunits of the condensin complex in higher eukaryotic cells has not been performed, and consequently the detailed contribution of different subunits to the formation of mitotic chromosome morphology is poorly understood. RESULTS We show that the SMC4 subunit of condensin is encoded by the essential gluon locus in Drosophila. DmSMC4 contains all the conserved domains present in other members of the structural-maintenance-of-chromosomes protein family. DmSMC4 is both nuclear and cytoplasmic during interphase, concentrates on chromatin during prophase, and localizes to the axial chromosome core at metaphase and anaphase. During decondensation in telophase, most of the DmSMC4 leaves the chromosomes. An examination of gluon mutations indicates that SMC4 is required for chromosome condensation and segregation during different developmental stages. A detailed analysis of mitotic chromosome structure in mutant cells indicates that although the longitudinal axis can be shortened normally, sister chromatid resolution is strikingly disrupted. This phenotype then leads to severe chromosome segregation defects, chromosome breakage, and apoptosis. CONCLUSIONS Our results demonstrate that SMC4 is critically important for the resolution of sister chromatids during mitosis prior to anaphase onset.
Collapse
Affiliation(s)
- S Steffensen
- Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto 4150, Portugal
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
OBJECTIVES To (a) develop an atlas of line drawings for the assessment and grading of narrowing and osteophyte (that is, changes of osteoarthritis) on knee radiographs, and (b) compare the performance of this atlas with that of the standard Osteoarthritis Research Society (OARS) photographic atlas of radiographs. METHODS Normal joint space widths (grade 0) for the medial and lateral tibiofemoral and medial and lateral patellofemoral compartments were obtained from a previous community study. Grades 1-3 narrowing in each compartment was calculated separately for men and women, grade 3 being bone on bone, grades 1 and 2 being two thirds and one third the value of grade 0. Maximum osteophyte size (grade 3) for each of eight sites was determined from 715 bilateral knee x ray films obtained in a knee osteoarthritis (OA) hospital clinic; grades 1-2 were calculated as two thirds and one third reductions in the area of grade 3. Drawings for narrowing and osteophyte were presented separately. 50 sets of bilateral knee x ray radiographs (standing, extended anteroposterior; flexed skyline) showing a spectrum of OA grades were scored by three observers, twice using the OARS atlas and twice using the drawn atlas. RESULTS Intraobserver and interobserver reproducibility was similar and generally good with both atlases, though varied according to site. All three observers preferred the line drawing atlas for ease and convenience of use. Higher scores for patellofemoral narrowing and lower scores for osteophyte, especially medial femoral osteophyte, were seen using the line drawing atlas, showing that the two atlases are not equivalent instruments. CONCLUSION A logically derived line drawing atlas for grading of narrowing and osteophyte at the knee has been produced. The atlas showed comparable reproducibility with the OARS atlas, but was discordant in several aspects of grading. Such a system has several theoretical and practical advantages and should be considered for use in knee OA studies.
Collapse
Affiliation(s)
- Y Nagaosa
- Academic Rheumatology, University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham NG5 1PB, UK
| | | | | | | | | |
Collapse
|
47
|
Abstract
The function of the neuronal differentiation gene daughterless (da) is required for the proper initiation of neuronal lineage development in all PNS lineages following the selection of neuronal precursor cells. Previous studies have shown that the ubiquitously expressed da protein is required for the proper expression of neuronal precursor genes and lineage identity genes in the PNS of Drosophila melanogaster embryos. These genes are required for differentiation and cell fate determination in the developing PNS. These findings, however, did not explain the failure of the nascent PNS precursors to undergo a normal cell cycle and divide. Here we show that four genes whose products are required for various stages of the cell cycle are misexpressed in the PNS of da mutant embryos. This suggests that all aspects of PNS precursor differentiation examined so far are under the transcriptional control of da.
Collapse
Affiliation(s)
- B Hassan
- Molecular, Cellular and Developmental Biology Program, Ohio State University, Columbus 43210-1002, USA
| | | |
Collapse
|
48
|
Abstract
Alkoptonuria is an inherited metabolic disorder which is associated with various systemic abnormalities and related to the deposition of homogentisic acid pigment in connective tissues. These pigmentary changes are termed "ochronosis". We describe two patients with ochronotic arthropathy who presented with progressive and advanced degenerative changes in the lumbo-sacral spine. The literature, differential diagnosis and management of this rare condition are reviewed in this article. Management is usually conservative, but replacement surgery may be offered for severely affected major joints.
Collapse
Affiliation(s)
- N Hamdi
- Department of Orthopaedic Surgery, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
| | | | | |
Collapse
|
49
|
Hassan B, Tung K, Weeks R, Mead GM. The management of inferior vena cava obstruction complicating metastatic germ cell tumors. Cancer 1999; 85:912-8. [PMID: 10091770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
BACKGROUND Inferior vena cava obstruction (IVCO) is a poorly characterized complication of metastatic germ cell tumor (GCT). The authors identified 31 cases to describe the clinical features, radiologic findings, complications, and treatment of this clinical entity. METHODS Patients with GCT and IVCO were identified from case records of a GCT database. The records of 333 male patients with metastatic GCT (27% with seminoma and 73% with nonseminomatous GCTs) were screened for either clinical or computed tomography (CT) scan evidence of inferior vena cava compression or involvement. RESULTS Thirty-one patients were identified (9.3% of patients with metastatic GCT). Common presenting symptoms were leg swelling and dilated abdominal wall veins. Approximately 29% of patients had thromboembolic complications and there was a single case of fatal pulmonary embolism. Nine patients had no clinical features at presentation but either had CT scan evidence of IVCO or developed symptoms during treatment. Right-sided testicular primary tumors were associated more frequently with IVCO compared with left-sided primary tumors (14% vs. 4% of cases of metastatic GCT, respectively). All patients had an abdominal mass measuring > 5 cm in maximum transverse dimension. CONCLUSIONS The authors recommend careful clinical and radiologic evaluation for the presence of IVCO in cases of bulky metastatic GCT. A high index of suspicion must accompany the evaluation of a patient with a right-sided primary testicular tumor and a paracaval abdominal mass measuring > 5 cm in maximum transverse dimension. When IVCO is identified, prophylactic anticoagulation is recommended.
Collapse
Affiliation(s)
- B Hassan
- Wessex Medical Oncology Unit, Royal South Hants Hospital, Southampton, United Kingdom
| | | | | | | |
Collapse
|
50
|
O'Donnell PG, Jackson SA, Tung KT, Hassan B, Wilkins B, Mead GM. Radiological appearances of lymphomas arising from mucosa-associated lymphoid tissue (MALT) in the lung. Clin Radiol 1998; 53:258-63. [PMID: 9585040 DOI: 10.1016/s0009-9260(98)80123-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
We review the radiological findings in 13 patients with histologically proven (n = 10) or clinically diagnosed (n = 3) lymphomas arising in mucosa-associated lymphoid tissue (MALT) of the lung. These rare B-cell lymphomas typically follow an indolent course, and many cases are still being incorrectly described in current radiological literature under the term pseudolymphoma. The patients frequently give a history of autoimmune disease involving the affected organ, and involvement of another mucosal site as part of a disseminated MALT lymphoma, is common. The radiographic patterns of pulmonary parenchymal involvement in lung MALT lymphomas have been reviewed, and correlation made with their clinical behaviour.
Collapse
Affiliation(s)
- P G O'Donnell
- Department of Radiology, Royal South Hants Hospital, Southampton, UK
| | | | | | | | | | | |
Collapse
|